What is NUTRA PHARMA CORP's earnings per share (EPS)?

NUTRA PHARMA CORP (NPHC) reported diluted earnings per share of $0.00 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

NUTRA PHARMA CORP (NPHC) Financials

NPHC

FY2025 annual

Revenue $258K +4.6% YoY

Net Income -$2.0M -59.2% YoY

EPS (Diluted) $0.00 YoY not available

Free Cash Flow -$1.2M YoY not available

Market Cap $716K as of Oct 16, 2026

Price / Sales 4.5x on $161K revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book n/m negative shareholder equity, so no book multiple, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 16, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 19, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 19, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NPHC SEC filings page.

NUTRA PHARMA CORP (NPHC) reported $258K in revenue for fiscal year 2025, up 4.6% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NPHC FY2025 2026-10-04

Gross-margin expansion has not produced operating stability: FY2025 paired better unit economics with larger losses and continued external financing.

Gross margin climbed from 13.6% in FY2023 to 76.3% in FY2025, yet the operating loss widened to $1.5M from $887K. That disconnect means the improvement in gross profit was more than absorbed below the gross-profit line, rather than flowing through to the bottom line.

Cash conversion deteriorated sharply: operating cash outflow increased from $424K in FY2024 to $1.2M in FY2025, while free cash flow was -$1.2M. The close relationship between the operating loss and cash outflow suggests FY2025 losses were materially cash-consuming, not chiefly an accounting effect.

The balance sheet is financed from a very thin base: FY2025 liabilities were $17.4M against $623K of assets, producing negative equity of $16.8M and a 0.0x current ratio. A 0.3-month liquidity comparison and $1.2M of financing inflow alongside operating cash outflow indicate that reported activity depended heavily on financing rather than internally generated cash.

Financial Health Signals

Financial health score not available

NUTRA PHARMA CORP does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-215.81

NUTRA PHARMA CORP scores -215.81, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($716K) relative to total liabilities ($17.4M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

6/9

NUTRA PHARMA CORP passes 6 of 9 financial strength tests. 1 of 4 profitability signals pass, all 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

NUTRA PHARMA CORP reported a net loss of $2.0M while operations used $1.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

NUTRA PHARMA CORP reported an operating loss of $1.5M against $23K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$34K

YoY-59.2%

QoQ+26.5%

5Y CAGR+2.5%

10Y CAGR+1.2%

NUTRA PHARMA CORP generated $34K in revenue in Q2 2026. This represents a decrease of 59.2% from the same quarter a year earlier. Against the prior quarter it is up 26.5%.

EBITDA

-$433K

YoY-50.7%

QoQ-15.0%

NUTRA PHARMA CORP's EBITDA was -$433K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 50.7% from the same quarter a year earlier. Against the prior quarter it is down 15.0%.

EPS (Diluted)

$0.00

NUTRA PHARMA CORP earned $0.00 per diluted share (EPS) in Q2 2026.

Net Income

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

Debt $135K

YoY-2.6%

QoQ-0.7%

NUTRA PHARMA CORP carried $135K in long-term debt as of Q2 2026, with $21.7M of liabilities due within a year; cash and equivalents are not reported for that period.

Shares Outstanding

7.16B

YoY+0.8%

QoQ0.0%

NUTRA PHARMA CORP had 7.16B shares outstanding in Q2 2026. This represents an increase of 0.8% from the same quarter a year earlier. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

94.7%

YoY+19.6pp

QoQ+102.0pp

5Y change+24.2pp

10Y change+29.6pp

NUTRA PHARMA CORP's gross margin was 94.7% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 19.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 102.0 percentage points.

Operating Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not reported for Q2 2026.

Return on Equity

Not reported for Q2 2026.

Capital Allocation

None of these metrics is reported for Q2 2026.

NPHC Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NPHC quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$161K	$258K+4.6%	$246K+19.8%	$206K+41.0%	$146K+49.2%	$98K+88.3%	$52K-50.3%	$104K-20.1%	$131K+7.9%	$121K-28.1%	$168K-42.2%	$291K-51.0%	$595K+467.1%	$105K-48.4%	$203K+27.4%	$160K
Cost of Revenue	$133K	$184K+116.5%	$85K-52.2%	$178K+9.0%	$163K+294.6%	$41K	N/A	N/A	$69K+155.6%	$27K-31.0%	$39K-40.8%	$66K-42.4%	$114K+177.7%	$41K-72.1%	$148K-83.2%	$880K
Gross Profit	$79K	$197K+21.8%	$161K+475.9%	$28K+264.5%	-$17K-301.3%	$8K-43.2%	$15K-57.0%	$35K+146.9%	$14K-85.1%	$94K-27.3%	$129K-42.6%	$225K-53.0%	$480K+654.2%	$64K+14.4%	$56K+107.7%	-$720K
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$3K-96.6%	$91K
SG&A Expenses	$272K	$701K-37.7%	$1.1M-4.4%	$1.2M-43.5%	$2.1M+8.1%	$1.9M+75.1%	$1.1M-8.4%	$1.2M	N/A	$1.5M	N/A	N/A	$2.7M	N/A	N/A	N/A
Operating Income	-$1.6M	-$1.5M-66.5%	-$878K+1.0%	-$887K+53.5%	-$1.9M+4.1%	-$2.0M-115.0%	-$925K+24.8%	-$1.2M	N/A	-$1.4M	N/A	N/A	-$2.2M	N/A	N/A	N/A
EBITDA	N/A	-$1.5M-66.7%	-$871K-0.3%	-$869K+53.9%	-$1.9M+4.8%	-$2.0M-114.9%	-$921K+24.9%	-$1.2M	N/A	-$1.4M	N/A	N/A	-$2.2M	N/A	N/A	N/A
Interest Expense	$24K	$23K+7.7%	$21K+12.9%	$19K+9.8%	$17K-6.1%	$18K-94.2%	$316K+29.4%	$244K-57.5%	$574K+67.3%	$343K+16.8%	$294K-32.4%	$435K+239.2%	$128K-18.6%	$157K+2.5%	$153K-63.8%	$424K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	N/A
Net Income	N/A	-$2.0M-59.2%	-$1.3M+7.7%	-$1.4M	N/A	N/A	-$769K	N/A	N/A	N/A	N/A	N/A	-$2.5M	N/A	N/A	N/A
EPS (Basic)	N/A	$0.00	$0.00	$0.00	$0.00+100.0%	$0.00	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	$0.00	$0.00	$0.00	$0.00	$0.00+100.0%	$0.00	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	7.78B+1.4%	7.67B+0.9%	7.61B-60.2%	19.10B+164.0%	7.23B	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$34K-59.2%	$27K-63.2%	$29K-64.7%	$70K-6.3%	$85K+63.5%	$74K+96.1%	$82K+74.1%	$75K+45.3%
Cost of Revenue	$25K-56.9%	$29K-36.8%	$45K+123.5%	$34K+43.5%	$59K+215.3%	$46K+105.8%	$20K-2.7%	$24K-4.3%
Gross Profit	$33K-48.6%	-$2K-103.4%	-$16K-169.8%	$65K-8.7%	$63K+91.7%	$59K+68.0%	$23K-15.2%	$71K+164.1%
SG&A Expenses	$185K-49.5%	$170K-59.3%	-$504K-289.9%	$421K+64.7%	$366K+33.5%	$418K+26.5%	$265K+13.5%	$255K-9.0%
Operating Income	-$435K-49.9%	-$379K-8.4%	-$466K-160.5%	-$356K-92.7%	-$291K-32.4%	-$350K-18.5%	-$179K-27.6%	-$185K-11.5%
EBITDA	-$433K-50.7%	-$377K-8.4%	-$463K-161.8%	-$353K-93.2%	-$287K-32.0%	-$348K-18.5%	-$177K-27.9%	-$183K-14.1%
Interest Expense	$6K+12.6%	$6K+7.5%	$6K+6.8%	$6K+6.8%	$6K+6.8%	$6K+10.6%	$6K+12.6%	$5K+12.6%
Net Income	N/A	-$460K+67.3%	-$489K-111.6%	-$524K-100.8%	$370K+200.7%	-$1.4M-229.1%	-$231K+5.0%	-$261K+6.4%
EPS (Basic)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
EPS (Diluted)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Diluted Shares (Avg)	8.07B-78.6%	8.01B+4.4%	N/A	7.82B+2.1%	37.73B+392.7%	7.68B+0.4%	N/A	7.66B+0.6%

Not reported in any period shown, so not listed: R&D Expenses, Income Tax.

NPHC Balance Sheet

NPHC quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$623K+3.9%	$599K-6.4%	$640K-15.2%	$755K-3.2%	$780K+158.5%	$302K-11.2%	$340K+140.3%	$141K-63.7%	$390K+81.8%	$214K-44.7%	$388K+0.1%	$387K+199.4%	$129K-57.3%	$303K+32.1%	$229K
Current Assets	$460K+22.6%	$375K+19.4%	$314K-5.9%	$334K-37.5%	$534K+864.4%	$55K-4.2%	$58K-49.9%	$115K-67.7%	$358K+93.2%	$185K-47.0%	$349K+2.2%	$342K+284.6%	$89K-64.0%	$247K+56.0%	$158K
Cash & Equivalents	$12K-66.6%	$36K	$0	$0-100.0%	$91K	N/A	N/A	N/A	N/A	$31K+353.5%	$7K-55.6%	$16K+234.7%	$5K-38.6%	$8K	$0
Short-Term Investments	$18K0.0%	$18K-50.0%	$35K	$0	$0	N/A	N/A	N/A	N/A	$0	$0	$0	$0	$0	$0
Inventory	$20K+10.4%	$18K-9.5%	$20K-18.1%	$24K-23.7%	$31K+493.6%	$5K-35.5%	$8K-76.8%	$35K+75.3%	$20K-21.2%	$26K-52.7%	$54K+15.1%	$47K+838.9%	$5K	$0-100.0%	$118K
Accounts Receivable	N/A	N/A	$22K+3.5%	$22K-52.9%	$46K+24.1%	$37K+14.2%	$32K+90.3%	$17K+12.7%	$15K-50.6%	$31K+39.3%	$22K-82.7%	$127K+1043.2%	$11K-70.9%	$38K	$0
Long-Term Investments	$0	$0	$0	$0	$0	N/A	N/A	N/A	N/A	$0	$0	$0	$0	$0	$0
Total Liabilities	$17.4M+13.2%	$15.4M+6.9%	$14.4M+9.7%	$13.1M-39.4%	$21.7M+83.6%	$11.8M-2.0%	$12.0M+98.1%	$6.1M+4.8%	$5.8M+23.6%	$4.7M+18.4%	$4.0M-0.5%	$4.0M-8.4%	$4.3M+12.1%	$3.9M-6.3%	$4.1M
Current Liabilities	$17.3M+13.4%	$15.3M+7.7%	$14.2M+11.6%	$12.7M-39.9%	$21.1M+84.1%	$11.5M+4.5%	$11.0M+82.4%	$6.0M+3.9%	$5.8M+24.8%	$4.6M+23.8%	$3.8M-5.0%	$4.0M-9.1%	$4.3M+12.1%	$3.9M-6.3%	$4.1M
Non-Current Liabilities	$137K-2.5%	$140K-40.9%	$237K-45.1%	$432K-16.6%	$517K+65.2%	$313K-70.2%	$1.1M-82.7%	$6.1M	$0-100.0%	$42K-79.6%	$208K+593.5%	$30K	$0	$0	$0
Long-Term Debt	$137K-2.5%	$140K-2.4%	$144K-98.2%	$8.2M	N/A	$215K	N/A	$51K	N/A	N/A	$147K-72.9%	$541K-21.6%	$690K	N/A	N/A
Total Equity	-$16.8M-13.6%	-$14.8M-7.6%	-$13.8M-11.2%	-$12.4M+40.7%	-$20.9M-81.6%	-$11.5M+1.8%	-$11.7M-97.1%	-$5.9M-9.7%	-$5.4M-20.8%	-$4.5M-25.2%	-$3.6M+0.6%	-$3.6M+14.8%	-$4.2M-18.0%	-$3.6M+8.6%	-$3.9M
Retained Earnings	-$78.3M-2.7%	-$76.2M-1.7%	-$74.9M-1.9%	-$73.6M+10.0%	-$81.7M-19.1%	-$68.6M-1.1%	-$67.9M-10.8%	-$61.3M-6.8%	-$57.4M-7.6%	-$53.4M-6.9%	-$49.9M-12.1%	-$44.5M-6.0%	-$42.0M-11.5%	-$37.6M-10.6%	-$34.0M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$623K-27.5%	$617K-20.5%	$623K+3.9%	$710K+27.0%	$859K+36.2%	$775K+24.9%	$599K-6.4%	$559K-21.4%
Current Assets	$463K-30.4%	$499K-9.5%	$460K+22.6%	$545K+75.4%	$665K+84.8%	$552K+72.5%	$375K+19.4%	$311K-14.6%
Cash & Equivalents	N/A	$22K+57.8%	$12K-66.6%	$4K	$79K	$14K	$36K	$0
Short-Term Investments	$18K0.0%	$18K0.0%	$18K0.0%	$18K0.0%	$18K0.0%	$18K0.0%	$18K-50.0%	$18K
Inventory	$24K+50.1%	$24K+33.8%	$20K+10.4%	$18K+2.6%	$16K-34.1%	$18K-5.6%	$18K-9.5%	$17K-41.3%
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$23K+5.4%
Long-Term Investments	N/A	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$21.8M+30.8%	$17.9M+5.2%	$17.4M+13.2%	$17.1M+10.9%	$16.7M+9.9%	$17.0M+14.7%	$15.4M+6.9%	$15.4M+8.0%
Current Liabilities	$21.7M+31.1%	$17.7M+5.3%	$17.3M+13.4%	$16.9M+11.2%	$16.6M+10.4%	$16.8M+15.4%	$15.3M+7.7%	$15.2M+9.1%
Non-Current Liabilities	$135K-2.6%	$136K-2.6%	$137K-2.5%	$138K-16.7%	$138K-27.0%	$139K-34.8%	$140K-40.9%	$165K-42.2%
Long-Term Debt	$135K-2.6%	$136K-2.6%	$137K-2.5%	$138K-2.5%	$138K-2.5%	$139K-98.3%	$140K-2.4%	$141K-98.3%
Total Equity	-$21.2M-34.0%	-$17.3M-6.5%	-$16.8M-13.6%	-$16.4M-10.3%	-$15.8M-8.8%	-$16.2M-14.2%	-$14.8M-7.6%	-$14.8M-9.6%
Retained Earnings	-$82.7M-7.0%	-$78.7M-1.4%	-$78.3M-2.7%	-$77.8M-2.4%	-$77.3M-2.0%	-$77.6M-3.0%	-$76.2M-1.7%	-$76.0M-1.7%

Not reported in any period shown, so not listed: Goodwill.

NPHC Cash Flow Statement

NPHC quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$1.0M	-$1.2M-174.5%	-$424K+22.9%	-$550K+27.9%	-$762K+56.3%	-$1.7M-98.7%	-$878K-18.1%	-$744K	N/A	-$1.1M	N/A	-$1.0M-587.4%	-$148K+72.1%	-$531K+26.4%	-$721K	N/A
Depreciation & Amortization	N/A	$11K+43.1%	$7K-59.1%	$18K-19.8%	$23K+149.7%	$9K+137.1%	$4K+2.5%	$4K-37.3%	$6K-5.1%	$6K-28.0%	$9K-22.2%	$11K-32.4%	$17K+10.8%	$15K-0.1%	$15K-6.6%	$16K
Stock-Based Compensation	N/A	$27K	N/A	N/A	$21K-86.6%	$154K+1705.9%	$9K-88.1%	$72K+2.1%	$70K-4.9%	$74K-81.2%	$391K-85.8%	$2.7M+436.0%	$512K-63.2%	$1.4M-22.6%	$1.8M+110.7%	$854K
Capital Expenditures	N/A	$26K	N/A	N/A	$58K+48.5%	$39K+561.2%	$6K	N/A	N/A	$9K+169.5%	$3K+371.0%	$718-96.7%	$22K	N/A	$0-100.0%	$1K
Free Cash Flow	N/A	-$1.2M	N/A	N/A	-$820K+54.0%	-$1.8M-101.8%	-$884K	N/A	N/A	-$1.1M	N/A	-$1.0M-500.5%	-$170K	N/A	-$721K	N/A
Investing Cash Flow	N/A	-$51K-223.6%	$41K-64.8%	$117K+329.8%	$27K+109.3%	-$294K-4871.1%	-$6K	N/A	N/A	-$9K-169.5%	-$3K-371.0%	-$718+96.7%	-$22K	N/A	$0+100.0%	-$1K
Financing Cash Flow	$971K	$1.2M+184.1%	$419K-3.1%	$433K-32.8%	$644K-69.7%	$2.1M+140.8%	$884K+18.9%	$744K	N/A	$1.1M	N/A	$1.0M+459.5%	$181K-65.8%	$528K-27.5%	$729K	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$251K+12.9%	-$328K+19.1%	-$220K-23.3%	-$251K-1414.8%	-$288K-208.0%	-$405K-136.6%	-$178K+4.3%	$19K+122.7%
Depreciation & Amortization	$2K-25.5%	$3K+16.6%	$3K+38.3%	$3K+48.9%	$3K+70.1%	$2K+15.3%	$2K0.0%	$2K-65.8%
Stock-Based Compensation	N/A	$11K	N/A	$9K	$2K	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	$0	$0	$0	$26K	N/A	N/A
Free Cash Flow	N/A	N/A	-$220K	-$251K	-$288K	-$431K	N/A	N/A
Investing Cash Flow	N/A	N/A	$0-100.0%	$0-100.0%	-$25K	-$26K	$8K-90.1%	$34K+1.4%
Financing Cash Flow	$229K-39.4%	$337K-17.4%	$228K+10.7%	$175K+430.3%	$379K+300.1%	$408K+138.6%	$206K+101.2%	-$53K-204.7%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

NPHC Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NPHC quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	76.3%+10.8pp	65.6%+51.9pp	13.6%+25.3pp	-11.7%-20.4pp	8.7%-20.1pp	28.7%-4.5pp	33.3%+22.5pp	10.8%-67.0pp	77.8%+0.9pp	76.9%-0.6pp	77.4%-3.4pp	80.8%+20.0pp	60.7%+33.4pp	27.4%	-451.1%
Operating Margin	-567.6%	-356.6%	-431.5%	-1308.2%	-2034.5%	-1782.3%	-1178.1%	N/A	-1142.3%	N/A	N/A	-370.4%	N/A	N/A	N/A
Net Margin	-794.8%	-522.0%	-677.8%	N/A	N/A	-1482.1%	N/A	N/A	N/A	N/A	N/A	-426.1%	N/A	N/A	N/A
Return on Assets	-328.8%-114.4pp	-214.5%+3.1pp	-217.6%	N/A	N/A	-254.9%	N/A	N/A	N/A	N/A	N/A	-654.1%	N/A	N/A	N/A
Current Ratio	0.030.0x	0.020.0x	0.020.0x	0.030.0x	0.030.0x	0.000.0x	0.010.0x	0.020.0x	0.060.0x	0.04-0.1x	0.090.0x	0.09+0.1x	0.020.0x	0.060.0x	0.04
Asset Turnover	0.410.0x	0.41+0.1x	0.32+0.1x	0.19+0.1x	0.130.0x	0.17-0.1x	0.31-0.6x	0.92+0.6x	0.31-0.5x	0.790.0x	0.75-0.8x	1.54+0.7x	0.81+0.1x	0.670.0x	0.70
FCF Margin	-461.9%	N/A	N/A	-562.7%	-1824.8%	-1703.4%	N/A	N/A	-948.5%	N/A	-349.8%	-28.5%	N/A	-354.8%	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	94.7%+19.6pp	-7.3%-87.2pp	-54.4%-81.9pp	91.9%-2.3pp	75.0%+11.0pp	79.9%-13.3pp	27.5%-28.9pp	94.3%+42.4pp
Operating Margin	-1263.6%	-1391.9%	-1614.2%	-506.9%	-343.7%	-472.9%	-218.5%	-246.4%
Net Margin	N/A	-1687.1%	-1692.5%	-745.3%	437.2%	-1899.2%	-282.0%	-347.6%
Return on Assets	N/A	-74.6%+106.7pp	-78.5%-39.9pp	-73.8%-27.1pp	43.0%+101.2pp	-181.2%-112.5pp	-38.5%-0.6pp	-46.7%-7.5pp
Current Ratio	0.020.0x	0.030.0x	0.030.0x	0.030.0x	0.040.0x	0.030.0x	0.020.0x	0.020.0x
Asset Turnover	0.060.0x	0.04-0.1x	0.05-0.1x	0.100.0x	0.100.0x	0.100.0x	0.14+0.1x	0.13+0.1x
FCF Margin	N/A	N/A	-761.6%	-357.0%	-341.1%	-582.7%	N/A	N/A

Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Note: Shareholder equity is negative (-$16.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.03), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
NUTRA PHARMA CORP NPHC	FY2025	$258K	-$2.0M	N/A	$716K	—
KAYA HOLDINGS INC KAYS	FY2024	$7K	N/A	N/A	$892K	—
CANN AMERICAN CORP CNNA	FY2012	N/A	-$1.7M	N/A	$994K	—

Where NUTRA PHARMA CORP Ranks

Frequently Asked Questions

What is NUTRA PHARMA CORP's annual revenue?

NUTRA PHARMA CORP (NPHC) reported $258K in total revenue for fiscal year 2025. This represents a 4.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is NUTRA PHARMA CORP's revenue growing?

NUTRA PHARMA CORP (NPHC) revenue grew by 4.6% year-over-year, from $246K to $258K in fiscal year 2025.

Is NUTRA PHARMA CORP profitable?

No, NUTRA PHARMA CORP (NPHC) reported a net income of -$2.0M in fiscal year 2025.

What is NUTRA PHARMA CORP's EBITDA?

NUTRA PHARMA CORP (NPHC) had EBITDA of -$1.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does NUTRA PHARMA CORP have?

As of fiscal year 2025, NUTRA PHARMA CORP (NPHC) had $12K in cash and equivalents against $137K in long-term debt.

What is NUTRA PHARMA CORP's gross margin?

NUTRA PHARMA CORP (NPHC) had a gross margin of 76.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is NUTRA PHARMA CORP's free cash flow?

NUTRA PHARMA CORP (NPHC) recorded an outflow of $1.2M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is NUTRA PHARMA CORP's operating cash flow?

NUTRA PHARMA CORP (NPHC) recorded an outflow of $1.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are NUTRA PHARMA CORP's total assets?

NUTRA PHARMA CORP (NPHC) had $623K in total assets as of fiscal year 2025, including both current and long-term assets.

What are NUTRA PHARMA CORP's capital expenditures?

NUTRA PHARMA CORP (NPHC) invested $26K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does NUTRA PHARMA CORP have outstanding?

NUTRA PHARMA CORP (NPHC) had 7.10B shares outstanding as of fiscal year 2025.

What is NUTRA PHARMA CORP's current ratio?

NUTRA PHARMA CORP (NPHC) had a current ratio of 0.03 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is NUTRA PHARMA CORP's return on assets (ROA)?

NUTRA PHARMA CORP (NPHC) had a return on assets of -328.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is NUTRA PHARMA CORP's P/E ratio?

NUTRA PHARMA CORP (NPHC) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $716K as of Oct 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is NUTRA PHARMA CORP's price-to-sales ratio?

NUTRA PHARMA CORP (NPHC) trades at 4.5x sales, its market capitalization divided by revenue of $161K revenue, trailing 12 months to June 30, 2026. The market capitalization is $716K as of Oct 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does NUTRA PHARMA CORP's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, NUTRA PHARMA CORP (NPHC) held $30K in cash, cash equivalents and investments, and reported an operating cash outflow of $1.2M over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is NUTRA PHARMA CORP's debt-to-equity ratio negative or not reported?

NUTRA PHARMA CORP (NPHC) has negative shareholder equity of -$16.8M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is NUTRA PHARMA CORP's Altman Z-Score?

NUTRA PHARMA CORP (NPHC) has an Altman Z-Score of -215.81, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is NUTRA PHARMA CORP's Piotroski F-Score?

NUTRA PHARMA CORP (NPHC) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are NUTRA PHARMA CORP's earnings high quality?

NUTRA PHARMA CORP (NPHC) reported a net loss of $2.0M while operations used $1.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can NUTRA PHARMA CORP cover its interest payments?

NUTRA PHARMA CORP (NPHC) reported an operating loss of $1.5M against $23K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.